← Back to Screener
DaVita Inc. (DVA)
Price$149.33
Favorite Metrics
Price vs S&P 500 (26W)13.63%
Price vs S&P 500 (4W)-10.03%
Market Capitalization$9.99B
P/E Ratio (Annual)13.37x
All Metrics
P/CF (Annual)5.29x
Book Value / Share (Quarterly)$1.50
P/TBV (Annual)11.21x
Revenue Growth (3Y)5.53%
Cash Flow / Share (Quarterly)$19.12
Price vs S&P 500 (YTD)27.51%
Gross Margin (TTM)32.25%
Net Profit Margin (TTM)5.47%
EPS (TTM)$9.91
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$9.91
Revenue Growth (5Y)3.39%
EPS (Annual)$9.84
ROI (Annual)9.79%
Gross Margin (Annual)32.25%
Net Profit Margin (5Y Avg)6.34%
Cash / Share (Quarterly)$10.22
P/E Basic Excl Extra (TTM)13.37x
Revenue Growth QoQ (YoY)9.87%
EPS Growth (5Y)9.36%
P/E Normalized (Annual)13.37x
ROA (Last FY)4.27%
Revenue Growth TTM (YoY)6.46%
EBITD / Share (TTM)$34.37
ROE (5Y Avg)220.50%
Operating Margin (TTM)14.88%
Cash Flow / Share (Annual)$19.12
P/B Ratio82.44x
P/B Ratio (Quarterly)101.25x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.44x
Net Interest Coverage (TTM)3.46x
ROA (TTM)4.29%
EPS Growth QoQ (YoY)6.32%
EV / EBITDA (TTM)7.51x
EPS Incl Extra (Annual)$9.84
Current Ratio (Annual)1.29x
Quick Ratio (Quarterly)1.19x
3-Month Avg Trading Volume0.97M
52-Week Price Return6.64%
EV / Free Cash Flow (Annual)14.94x
P/E Incl Extra (TTM)13.37x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.29
P/S Ratio (Annual)0.73x
Asset Turnover (Annual)0.78x
52-Week High$159.42
Operating Margin (5Y Avg)14.24%
EPS Excl Extra (Annual)$9.84
CapEx CAGR (5Y)-3.11%
Tangible BV CAGR (5Y)-24.96%
26-Week Price Return20.51%
Quick Ratio (Annual)1.19x
13-Week Price Return41.09%
Total Debt / Equity (Annual)77.99x
Current Ratio (Quarterly)1.29x
Enterprise Value$19,582.016
Revenue / Share Growth (5Y)13.87%
Asset Turnover (TTM)0.78x
Book Value / Share Growth (5Y)-38.38%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)62.63x
Pretax Margin (Annual)9.87%
Cash / Share (Annual)$10.22
3-Month Return Std Dev52.08%
Gross Margin (5Y Avg)31.46%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)3.24%
EBITDA Interim CAGR (5Y)5.17%
ROE (Last FY)773.06%
Net Interest Coverage (Annual)3.46x
EPS Basic Excl Extra (Annual)$9.84
P/FCF (TTM)7.62x
Receivables Turnover (TTM)5.98x
EV / Free Cash Flow (TTM)14.94x
Total Debt / Equity (Quarterly)77.99x
EPS Incl Extra (TTM)$9.91
Receivables Turnover (Annual)5.37x
ROI (TTM)9.56%
P/S Ratio (TTM)0.73x
Pretax Margin (5Y Avg)10.58%
Revenue / Share (Annual)$179.79
Tangible BV / Share (Annual)$9.60
Forward P/E10.54x
Free OCF CAGR (5Y)0.09%
Price vs S&P 500 (52W)-27.99%
P/E Ratio (TTM)13.37x
EPS Growth TTM (YoY)-7.80%
Year-to-Date Return31.44%
5-Day Price Return-0.08%
EPS Normalized (Annual)$9.84
ROA (5Y Avg)4.56%
Net Profit Margin (Annual)5.47%
Month-to-Date Return-2.84%
Cash Flow / Share (TTM)$17.04
EBITD / Share (Annual)$34.38
EPS Growth (3Y)19.05%
Operating Margin (Annual)14.88%
LT Debt / Equity (Annual)75.76x
P/CF (TTM)5.29x
ROI (5Y Avg)8.24%
P/E Excl Extra (TTM)13.37x
LT Debt / Equity (Quarterly)75.76x
EPS Basic Excl Extra (TTM)$9.91
P/TBV (Quarterly)71.72x
P/B Ratio (Annual)101.25x
Inventory Turnover (TTM)62.63x
Pretax Margin (TTM)9.87%
Book Value / Share (Annual)$1.50
Price vs S&P 500 (13W)38.71%
Net Margin Growth (5Y)-3.98%
Beta0.84x
P/FCF (Annual)7.62x
Revenue / Share (TTM)$191.58
ROE (TTM)181.22%
52-Week Low$101.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.65
2.65
3.36
3.43
Industry Peers — Health Services(14)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
DVADaVita Inc. | 13.37x | 6.46% | 14.88% | 181.22% | $149.33 |
FMSFresenius Medical Care AG | 11.75x | 1.51% | 9.31% | 7.26% | $23.18 |
SHCSotera Health Company Common Stock | 59.47x | 5.74% | 25.41% | 14.98% | $16.28 |
PGNYProgyny, Inc. Common Stock | 24.25x | 10.40% | 6.62% | 11.37% | $18.64 |
AGLagilon health, inc. | — | -2.11% | -7.81% | -116.65% | $28.30 |
MCTACharming Medical Limited Class A Ordinary Shares | 414.66x | — | 15.45% | — | $29.36 |
VMDViemed Healthcare, Inc. Common Shares | 24.97x | 20.52% | 8.49% | 10.87% | $9.66 |
QIPTQuipt Home Medical Corp. Ordinary Shares | — | 9.52% | -1.22% | -10.47% | $3.65 |
PARKPark Dental Partners, Inc. Common Stock | 17.91x | — | 0.10% | — | $18.25 |
OAKUOak Woods Acquisition Corporation Class A Ordinary Shares | 174.54x | — | — | -0.64% | $12.20 |
OAKUROak Woods Acquisition Corporation Right | 174.54x | — | — | -0.64% | $0.16 |
About
DaVita is the largest U.S. dialysis provider, operating over 3,000 facilities globally and treating approximately 280,000 patients annually, with roughly 35% of U.S. market share. The company derives about two-thirds of U.S. sales from government payers (primarily Medicare) at regulated reimbursement rates. Though commercial insurers represent only 10% of U.S. patients served, they generate nearly all profits from the U.S. dialysis business, creating significant earnings sensitivity to commercial payer mix.